PIM1 and cancer: In fact, several clinical trials in advanced cancer patients combine Pim with a second targeted therapy, for example, with imatinib (targeting multiple tyrosine kinases in GIST, NCT05245968) [27], zimberelimab (a PD-1 inhibitor in PDAC, CRC and NSCLC, NCT04999761) [28], enzalutamide (antagonizing the androgen receptor in prostate cancer, jRCT2031230263) [29], and niraparib (a Poly(ADP-ribose) Polymerase (PARP) inhibitor in solid tumors, jRCT2031220179) [30].